Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 22Colorectal Neoplasms 14Ovarian Neoplasms 12Lung Neoplasms 10Neoplasm Metastasis 9Stomach Neoplasms 8Neoplasms 8Nasopharyngeal Carcinoma 8Leukemia, Myeloid, Acute 7Triple Negative Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Rectal Neoplasms 6Fallopian Tube Neoplasms 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Esophageal Squamous Cell Carcinoma 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Lymphoma, Non-Hodgkin 4Leukemia 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Carcinoma, Ovarian Epithelial 4Pancreatic Neoplasms 3Neoplasms by Site 3Lymphoma, Large B-Cell, Diffuse 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Multiple Myeloma 2

Interventions

osimertinib 1obinutuzumab 1midostaurin 1flumatinib 1fludarabine 1Radiotherapy 1Oxaliplatin 1Mitoxantrone 1Mercaptopurine 1Leucovorin 1Irinotecan 1Gemtuzumab 1Folfox protocol 1Fluorouracil 1Drug Therapy 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm, Residual × Drug Therapy × Clear all
NCT03512197 2023-08-21

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Novartis

Phase 3 Completed
511 enrolled 26 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡